1204219-80-6

Basic information

• Product Name: Dapagliflozin-d5
• Synonyms: Dapagliflozin-d5;(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-(ethoxy-1,1,2,2,2-d5)phenyl]methyl]phenyl]-D-glucitol
• CAS NO: 1204219-80-6
• Molecular Formula: C₂₁H₂₅ClO₆
• Molecular Weight: 413.90340889
• Mol File: 1204219-80-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: Dapagliflozin-d5(CAS DataBase Reference)
• NIST Chemistry Reference: Dapagliflozin-d5(1204219-80-6)
• EPA Substance Registry System: Dapagliflozin-d5(1204219-80-6)

Safety Data

• Hazardous Substances Data: 1204219-80-6(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 1204219-80-6 differently. You can refer to the following data:
1. Labeled Dapagliflozin, Dapagliflozin-d5 can be intended for use as an internal standard for the quantification of Dapagliflozin by GC- or LC-mass spectrometry.
2. Dapagliflozin-D5 is a labelled analogue of Dapagliflozin (D185370), a selective sodium-glucose cotransporter-2 inhibitor that reduces renal glucose reabsorption and is used to treat patients with type 2 diabetes.

Upstream product

• 1204219-63-5 4-bromo-1-chloro-2-(4-(ethoxy-1,1-d2)benzyl)benzene 
• 864070-18-8 4-(5-bromo-2-chlorobenzyl)phenol 
• 333361-51-6 4-bromo-1-chloro-2-(4-methoxybenzyl)benzene 
• 333361-49-2 (5-bromo-2-chlorophenyl)(4-methoxyphenyl)methanone 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 864070-37-1 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 59034-23-0 4-methylbenzenesulfonic acid [D₅]ethyl ester 
• 1204220-63-2 (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 864070-19-9 [4-(5-bromo-2-chloro-benzyl)-phenoxy]-tert-butyl-dimethyl-silane 
• 1204219-65-7 (3R,4S,5S,6R)-2-(4-chloro-3-(4-(ethoxy-1,1-d2)benzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 

Relevant articles and documents

Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes

SGLT2 inhibitors deuterated at sites susceptible to oxidative metabolism were found to have a slightly longer tmax and half-life (t 1/2), dose-dependent increase in urinary glucose excretion (UGE) in rats, and slightly superior effects on UGE in dogs while retaining similar in vitro inhibitory activities against hSGLT2. In particular, deuterated compound 41 has the potential to be a robust long-acting antidiabetic agent.

ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2

The present invention relates to new ethoxyphenylmethyl modulators of SGLT2, pharmaceutical compositions thereof, and methods of use thereof. (Formula I)